IL-33 promotes growth and liver metastasis of colorectal cancer in mice by remodeling the tumor microenvironment and inducing angiogenesis

Molecular Carcinogenesis

Volumn 56, Issue 1, 2017, Pages 272-287

  Zhang, Yu ^a   Davis, Celestia ^a   Shah, Sapana ^a   Hughes, Daniel ^a   Ryan, James C ^b   Altomare, Diego ^a   Peña, Maria Marjorette O ^a  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b ProteoGenomics LLC   (United States)

Author keywords

alarmin; colon cancer; cytokines; inflammation; myeloid cells

Indexed keywords

CD11B ANTIGEN; INTERLEUKIN 33;

ADENOCARCINOMA CELL LINE; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; C57BL 6 MOUSE; CANCER GROWTH; CARCINOMA CELL LINE; COLON CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; KNOCKOUT MOUSE; LIVER METASTASIS; MALE; MOUSE; MYELOID-DERIVED SUPPRESSOR CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR INVASION; TUMOR MICROENVIRONMENT; TUMOR PROMOTION; UPREGULATION; WILD TYPE MOUSE; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; COLON; COLORECTAL TUMOR; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LIVER; LIVER TUMOR; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; RECTUM; SECONDARY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; COLON; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-33; LIVER; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; RECTUM; TUMOR MICROENVIRONMENT;

EID: 85002369621     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22491     Document Type: Article

References (54)

1. Tenesa A, Dunlop MG. New insights into the aetiology of colorectal cancer from genome-wide association studies. Nat Rev Genet 2009; 10:353–358.
2. American Cancer Society. Cancer facts and figures 2012. Atlanta: American Cancer Society; 2012. pp. 25–26.
3. Nguyen DX, Bos PD, Massague J. Metastasis: From dissemination to organ-specific colonization. Nat Rev Cancer 2009; 9:274–284.
4. Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23:479–490.
5. Moussion C, Ortega N, Girard JP. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: A novel ‘alarmin’? PLoS ONE 2008; 3:e3331.
6. Haraldsen G, Balogh J, Pollheimer J, Sponheim J, Kuchler AM. Interleukin-33 − cytokine of dual function or novel alarmin? Trends Immunol 2009; 30:227–233.
7. Zhao W, Hu Z. The enigmatic processing and secretion of interleukin-33. Cell Mol Immunol 2010; 7:260–262.
8. Cayrol C, Girard JP. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Nat Acad Sci USA 2009; 106:9021–9026.
9. Liew FY, Pitman NI, McInnes IB. Disease-associated functions of IL-33: The new kid in the IL-1 family. Nat Rev Immunol 2010; 10:103–110.
10. Hayakawa H, Hayakawa M, Kume A, Tominaga S. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem 2007; 282:26369–26380.
11. Hu LA, Fu Y, Zhang DN, Zhang J. Serum IL-33 as a diagnostic and prognostic marker in non- small cell lung cancer. Asian Pac J Cancer Prev 2013; 14:2563–2566.
12. Bergis D, Kassis V, Ranglack A, et al. High serum levels of the interleukin-33 receptor soluble ST2 as a negative prognostic factor in hepatocellular carcinoma. Transl Oncol 2013; 6:311–318.
13. Sun P, Ben Q, Tu S, Dong W, Qi X, Wu Y. Serum interleukin-33 levels in patients with gastric cancer. Dig Dis Sci 2011; 56:3596–3601.
14. Byrne SN, Beaugie C, O'Sullivan C, Leighton S, Halliday GM. The immune-modulating cytokine and endogenous Alarmin interleukin-33 is upregulated in skin exposed to inflammatory UVB radiation. Am J Pathol 2011; 179:211–222.
15. Schmieder A, Multhoff G, Radons J. Interleukin-33 acts as a pro-inflammatory cytokine and modulates its receptor gene expression in highly metastatic human pancreatic carcinoma cells. Cytokine 2012; 60:514–521.
16. Jovanovic IP, Pejnovic NN, Radosavljevic GD, et al. Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells. Int J Cancer 2013; 34:1669–1682.
17. Yamada D, Rizvi S, Razumilava N, et al. IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanism. Hepatology 2015; 61:1627–1642.
18. Chen SF, Nieh S, Jao SW, et al. The paracrine effect of cancer-associated fibroblast-induced interleukin-33 regulates the invasiveness of head and neck squamous cell carcinoma. J Pathol 2013; 231:180–189.
19. Gao X, Wang X, Yang Q, et al. Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells. J Immunol 2015; 194:438–445.
20. Guabiraba R, Besnard AG, Menezes GB, et al. IL-33 targeting attenuates intestinal mucositis and enhances effective tumor chemotherapy in mice. Mucosal Immunol 2014; 7:1079–1093.
21. Cui G, Qi H, Gundersen MD, et al. Dynamics of the IL-33/ST2 network in the progression of human colorectal adenoma to sporadic colorectal cancer. Cancer Immunol Immunother 2015; 64:181–190.
22. Welkenhuysen M, Evers-Kiebooms G. General practitioners and predictive genetic testing for late-onset diseases in Flanders: What are their opinions and do they want to be involved? Community Genet 2002; 5:128–137.
23. Maywald RL, Doerner SK, Pastorelli L, et al. IL-33 activates tumor stroma to promote intestinal polyposis. Proc Nat Acad Sci USA 2015; 112:E2487–E2496.
24. Zhang Y, Davis C, Ryan J, Janney C, Pena MM. Development and characterization of a reliable mouse model of colorectal cancer metastasis to the liver. Clin Exp Metastasis 2013; 30:903–918.
25. Cohen ES, Scott IC, Majithiya JB, et al. Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation. Nat Commun 2015; 6:8327.
26. Erler JT, Bennewith KL, Nicolau M, et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006; 440:1222–1226.
27. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. Nat Rev Cancer 2009; 9:265–273.
28. Guo X, Oshima H, Kitmura T, Taketo MM, Oshima M. Stromal fibroblasts activated by tumor cells promote angiogenesis in mouse gastric cancer. J Biol Chem 2008; 283:19864–19871.
29. Stacker SA, Williams SP, Karnezis T, Shayan R, Fox SB, Achen MG. Lymphangiogenesis and lymphatic vessel remodelling in cancer. Nat Rev Cancer 2014; 14:159–172.
30. Pollheimer J, Bodin J, Sundnes O, et al. Interleukin-33 drives a proinflammatory endothelial activation that selectively targets nonquiescent cells. Arterioscler Thromb Vasc Biol 2013; 33:e47–e55.
31. Choi YS, Choi HJ, Min JK, et al. Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production. Blood 2009; 114:3117–3126.
32. Terzic J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology 2010; 138:2101–2114; e2105.
33. Priceman SJ, Sung JL, Shaposhnik Z, et al. Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: Combating tumor evasion of antiangiogenic therapy. Blood 2010; 115:1461–1471.
34. Bayne LJ, Beatty GL, Jhala N, et al. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 2012; 21:822–835.
35. Qian BZ, Li J, Zhang H, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011; 475:222–225.
36. Lamagna C, Aurrand-Lions M, Imhof BA. Dual role of macrophages in tumor growth and angiogenesis. J Leukoc Biol 2006; 80:705–713.
37. Acharyya S, Oskarsson T, Vanharanta S, et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 2012; 150:165–178.
38. Hiratsuka S, Watanabe A, Sakurai Y, et al. The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat Cell Biol 2008; 10:1349–1355.
39. Ichikawa M, Williams R, Wang L, Vogl T, Srikrishna G. S100A8/A9 activate key genes and pathways in colon tumor progression. Mol Cancer Res 2011; 9:133–148.
40. Gebhardt C, Nemeth J, Angel P, Hess J. S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol 2006; 72:1622–1631.
41. Lakatos PL, Lakatos L. Risk for colorectal cancer in ulcerative colitis: Changes, causes and management strategies. World J Gastroenterol 2008; 14:3937–3947.
42. Wang S, Liu Z, Wang L, Zhang X. NF-kappaB signaling pathway, inflammation and colorectal cancer. Cell Mol Immunol 2009; 6:327–334.
43. Popivanova BK, Kitamura K, Wu Y, et al. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest 2008; 118:560–570.
44. Moser AR, Pitot HC, Dove WF. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 1990; 247:322–324.
45. McClellan JL, Davis JM, Steiner JL, et al. Intestinal inflammatory cytokine response in relation to tumorigenesis in the Apc(Min/+) mouse. Cytokine 2012; 57:113–119.
46. Herbst A, Jurinovic V, Krebs S, et al. Comprehensive analysis of beta-catenin target genes in colorectal carcinoma cell lines with deregulated Wnt/beta-catenin signaling. BMC Genomics 2014; 15:74.
47. Chan JK, Roth J, Oppenheim JJ, et al. Alarmins: Awaiting a clinical response. J Clin Invest 2012; 122:2711–2719.
48. Bonilla WV, Frohlich A, Senn K, et al. The alarmin interleukin-33 drives protective antiviral CD8(+) T cell responses. Science 2012; 335:984–989.
49. Lim SY, Gordon-Weeks AN, Zhao L, et al. Recruitment of myeloid cells to the tumor microenvironment supports liver metastasis. Oncoimmunology 2013; 2:e23187.
50. Miller AM. Role of IL-33 in inflammation and disease. J Inflamm (Lond) 2011; 8:22.
51. Huang J, Soffer SZ, Kim ES, et al. Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis. Mol Cancer Res 2004; 2:36–42.
52. Edrei Y, Gross E, Corchia N, Abramovitch R. Improved efficacy of a novel anti-angiogenic drug combination (TL-118) against colorectal-cancer liver metastases; MRI monitoring in mice. Br J Cancer 2012; 107:658–666.
53. Gao K, Li X, Zhang L, et al. Transgenic expression of IL-33 activates CD8(+) T cells and NK cells and inhibits tumor growth and metastasis in mice. Cancer Lett 2013; 335:463–471.
54. Levescot A, Flamant S, Basbous S, et al. BCR-ABL-induced deregulation of the IL-33/ST2 pathway in CD34+ progenitors from chronic myeloid leukemia patients. Cancer Res 2014; 74:2669–2676.